Wanbury, a leading pharmaceutical company, has announced the commencement of its state-of-the-art API manufacturing facility in Tanuku, Andhra Pradesh, marking a significant step in its growth.

The company aims to achieve revenue growth, targeting approximately Rs. 100 crore from new products, including key APIs such as anti-tussive, antidepressant, and anticoagulant molecules. This strategic expansion is expected to meet global demand, enhancing Wanbury’s position in the API market and strengthening its presence in domestic and international markets. The company is set to start commercial production by Q4/FY2026 and anticipates substantial revenue generation, driven by the production of these high-value APIs.

Wanbury's commitment to quality and innovation underscores its strategic expansion into the global pharmaceutical market. With an investment of over Rs 100 crore, the Tanuku facility will support the company’s plans to increase its market share and offer reliable, high-quality products to meet healthcare needs worldwide.